According to the RNC Pharma® database “Audit of Retail Sales of Medicinal Products in Russia (total sell-out)”, retail sales of nasal decongestants (EphMRA group R01A7) reached RUB 28.9 billion (retail prices including VAT) in January–September 2025, with more than 230.9 million packages sold. Compared with the same period in 2024, sales increased by 9.7% in value and 3.2% in volume. This represents the lowest value growth and the highest volume growth seen in the past three years — in 2024 vs. 2023, sales rose by 13.7% in rubles and 1.6% in packages.

In September 2025, long-term dynamics reached +10.5% in value and +3.7% in volume. Interestingly, this was not the strongest growth month of the year — April and June–July 2025 showed even higher momentum, with value growth above 15% and volume growth between 6.4% and 8.2%. Still, September marked the absolute peak of demand, with 29.8 million packages sold for nearly RUB 4.0 billion.

Throughout the month, demand fluctuated noticeably. In early September, daily sales averaged around 870,000 packages, surpassing 1 million on September 8, and remaining above that threshold for six consecutive days. A brief decline occurred on September 14 — typically a weekend-related slowdown — but on September 15, pharmacies across Russia sold over 1.23 million packages of nasal decongestants worth RUB 168 million, averaging about 15 packages per pharmacy per day. A downward trend followed, continuing into mid-October.

In 2025, the nasal decongestant segment saw a change in market leadership. The Otrivin brand (Haleon, OTC division of GSK) took the top spot, accounting for over 15% of category sales and showing +28% growth in rubles. The previous long-term leader, Snoop (Nizhpharm Group), saw sales decline by 9%, dropping to second place with a 13% share. Rinonorm (Teva) ranked third, demonstrating the strongest growth among the top brands — +32% year-on-year in rubles.

Outside the top 10, Morelor (Yuzhpharm) showed +45% growth, reaching 18th place with a 1.2% market share. One of the fastest-growing products overall was Rinoxil (Flumed-Pharm, Republic of Moldova), whose value sales in Russian retail increased sixfold year-on-year.

Fig. Daily dynamics of nasal decongestant sales (EphMRA group R01A7) in the Russian retail pharmaceutical market (including online channel), September 2025